Psoriasis is chronic inflammatory disease of the immune system that mostly affects the skin and joints, but also may affect the fingernails, the toenails, and the inside of the mouth. In the United States it affects as many as 7.5 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium. Join Frank Narjes, a Principal Scientist at AstraZeneca as he discusses Psoriasis from a MedChem perspective, highlighting a novel orally bioavailable treatment of this prevalent autoimmune disease with the discovery of clinical candidate AZD0284. In this presentation he will prove that by inhibiting the function of the pro-inflammatory cytokine IL-17 or blockage of its receptor with antibodies positive results can be found in the clinic for diseases such as psoriasis, ankylosing spondylitis and rheumatoid arthritis.